• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

FLT3内部串联重复和酪氨酸激酶结构域突变对急性髓系白血病的预后意义:一项荟萃分析。

Prognostic significance of FLT3 internal tandem duplication and tyrosine kinase domain mutations for acute myeloid leukemia: a meta-analysis.

作者信息

Yanada M, Matsuo K, Suzuki T, Kiyoi H, Naoe T

机构信息

Department of Hematology, Nagoya University Graduate School of Medicine, Nagoya, Japan.

出版信息

Leukemia. 2005 Aug;19(8):1345-9. doi: 10.1038/sj.leu.2403838.

DOI:10.1038/sj.leu.2403838
PMID:15959528
Abstract

Two distinct forms of fms-like tyrosine kinase (FLT3) gene aberrations, internal tandem duplication (ITD) and tyrosine kinase domain (TKD) mutations, have been recognized in a substantial proportion of patients with acute myeloid leukemia (AML). To investigate their prognostic significance, we performed a meta-analysis of the four published studies that provided survival information according to the FLT3 status: ITD, TKD mutation, and wild type. The summary hazard ratios for disease-free survival (DFS) were 1.88 (95% confidence interval (CI) 1.58-2.23; P<0.001) for FLT3 mutations, 1.86 (95% CI: 1.52-2.29; P<0.001) for ITD, and 1.90 (95% CI: 1.40-2.60; P<0.001) for TKD mutation. The corresponding ratios for overall survival were 1.61 (95% CI: 1.37-1.89; P<0.001), 1.68 (95% CI: 1.39-2.03; P<0.001), and 1.37 (95% CI: 0.94-2.01; P=0.104). Neither white blood cell count at diagnosis nor cytogenetic risk category was a significant source of heterogeneity. These findings indicate that FLT3 mutations have an adverse effect on the outcome for AML, and that the negative impact of TKD mutation seems comparable to that of ITD with regard to DFS. Although it should be borne in mind that this meta-analysis was based on data abstracted from observational studies, these results may justify the risk-adapted therapeutic strategies for AML according to the FLT3 status.

摘要

在相当一部分急性髓系白血病(AML)患者中,已识别出两种不同形式的fms样酪氨酸激酶(FLT3)基因畸变,即内部串联重复(ITD)和酪氨酸激酶结构域(TKD)突变。为研究它们的预后意义,我们对四项已发表的研究进行了荟萃分析,这些研究根据FLT3状态(ITD、TKD突变和野生型)提供了生存信息。FLT3突变患者无病生存(DFS)的汇总风险比为1.88(95%置信区间(CI)1.58 - 2.23;P<0.001),ITD为1.86(9�%CI:1.52 - 2.29;P<0.001),TKD突变为1.90(95%CI:1.40 - 2.60;P<0.001)。总生存的相应比值分别为1.61(95%CI:1.37 - 1.89;P<0.001)、1.68(95%CI:1.39 - 2.03;P<0.001)和1.37(95%CI:0.94 - 2.01;P = 0.104)。诊断时的白细胞计数和细胞遗传学风险类别均不是异质性的显著来源。这些发现表明,FLT3突变对AML的预后有不利影响,并且就DFS而言,TKD突变的负面影响似乎与ITD相当。尽管应牢记此荟萃分析基于从观察性研究中提取的数据,但这些结果可能为根据FLT3状态制定AML的风险适应性治疗策略提供依据。

相似文献

1
Prognostic significance of FLT3 internal tandem duplication and tyrosine kinase domain mutations for acute myeloid leukemia: a meta-analysis.FLT3内部串联重复和酪氨酸激酶结构域突变对急性髓系白血病的预后意义:一项荟萃分析。
Leukemia. 2005 Aug;19(8):1345-9. doi: 10.1038/sj.leu.2403838.
2
Internal tandem duplication of fms-like tyrosine kinase 3 is associated with poor outcome in patients with myelodysplastic syndrome.FMS样酪氨酸激酶3的内部串联重复与骨髓增生异常综合征患者的不良预后相关。
Cancer. 2004 Sep 1;101(5):989-98. doi: 10.1002/cncr.20440.
3
Risk assessment in patients with acute myeloid leukemia and a normal karyotype.急性髓系白血病且核型正常患者的风险评估
Clin Cancer Res. 2005 Feb 15;11(4):1416-24. doi: 10.1158/1078-0432.CCR-04-1552.
4
Acquisition of FLT3 or N-ras mutations is frequently associated with progression of myelodysplastic syndrome to acute myeloid leukemia.FLT3或N-ras突变的获得常与骨髓增生异常综合征进展为急性髓系白血病相关。
Leukemia. 2004 Mar;18(3):466-75. doi: 10.1038/sj.leu.2403274.
5
FLT3-TKD mutation in childhood acute myeloid leukemia.儿童急性髓系白血病中的FLT3-TKD突变
Leukemia. 2003 May;17(5):883-6. doi: 10.1038/sj.leu.2402928.
6
Absence of the wild-type allele predicts poor prognosis in adult de novo acute myeloid leukemia with normal cytogenetics and the internal tandem duplication of FLT3: a cancer and leukemia group B study.野生型等位基因缺失预示着细胞遗传学正常且伴有FLT3内部串联重复的成人初发急性髓系白血病预后不良:一项癌症与白血病B组研究。
Cancer Res. 2001 Oct 1;61(19):7233-9.
7
Incidence and prognostic value of FLT3 internal tandem duplication and D835 mutations in acute myeloid leukemia.急性髓系白血病中FLT3内部串联重复和D835突变的发生率及预后价值
Haematologica. 2003 Jan;88(1):19-24.
8
Clinical impact of internal tandem duplications and activating point mutations in FLT3 in acute myeloid leukemia in elderly patients.老年急性髓系白血病患者中FLT3内部串联重复和激活点突变的临床影响
Eur J Haematol. 2004 May;72(5):307-13. doi: 10.1111/j.1600-0609.2004.00225.x.
9
Meta-analysis for the potential application of FLT3-TKD mutations as prognostic indicator in non-promyelocytic AML.FLT3-TKD 突变作为非早幼粒细胞性急性髓系白血病预后指标的潜在应用的荟萃分析。
Leuk Res. 2012 Feb;36(2):186-91. doi: 10.1016/j.leukres.2011.08.014. Epub 2011 Sep 9.
10
Better detection of FLT3 internal tandem duplication using peripheral blood plasma DNA.利用外周血血浆DNA更好地检测FLT3内部串联重复。
Leukemia. 2003 Jan;17(1):114-9. doi: 10.1038/sj.leu.2402743.

引用本文的文献

1
Assessment of chromatin remodeling of acute myeloid leukemia cells treated with gilteritinib: a case report.吉瑞替尼治疗急性髓系白血病细胞染色质重塑的评估:一例报告
J Med Case Rep. 2025 Apr 3;19(1):153. doi: 10.1186/s13256-025-05186-2.
2
Maintenance therapy with the FMS-like tyrosine kinase 3 inhibitor gilteritinib in patients with FMS-like tyrosine kinase 3-internal tandem duplication acute myeloid leukemia: A phase 2 study.FMS样酪氨酸激酶3抑制剂吉列替尼用于FMS样酪氨酸激酶3内部串联重复急性髓系白血病患者的维持治疗:一项2期研究。
Cancer. 2025 Feb 15;131(4):e35746. doi: 10.1002/cncr.35746.
3
New Approvals Advancing Blood Cancer Medicine.
新批准推动血癌药物发展。
Blood Cancer Discov. 2025 Jan 8;6(1):5-9. doi: 10.1158/2643-3230.BCD-24-0300.
4
Phase 3 study of gilteritinib versus salvage chemotherapy in predominantly Asian patients with relapsed/refractory FLT3-mutated acute myeloid leukemia.在主要为亚洲患者中开展的对比挽救化疗的 3 期研究,评估 gilteritinib 在复发/难治性 FLT3 突变型急性髓系白血病中的应用。
Leukemia. 2024 Nov;38(11):2410-2418. doi: 10.1038/s41375-024-02382-9. Epub 2024 Sep 5.
5
Molecular Features and Treatment Paradigms of Acute Myeloid Leukemia.急性髓系白血病的分子特征与治疗模式
Biomedicines. 2024 Aug 6;12(8):1768. doi: 10.3390/biomedicines12081768.
6
Clinical profile of -ITD mutation in West Algerian population with acute myeloid leukemia.阿尔及利亚西部急性髓系白血病患者中-ITD突变的临床特征
Mol Biol Res Commun. 2024;13(3):175-182. doi: 10.22099/mbrc.2024.49437.1955.
7
Clinical Outcomes and Treatment Patterns in Adults With FLT3-ITD Acute Myeloid Leukemia Undergoing Allogeneic Hemopoietic Cell Transplantation in the United States and Canada.美国和加拿大接受异基因造血细胞移植的 FLT3-ITD 急性髓系白血病成人的临床结局和治疗模式。
Transplant Cell Ther. 2024 Jul;30(7):683.e1-683.e13. doi: 10.1016/j.jtct.2024.04.016. Epub 2024 Apr 23.
8
TP-0184 inhibits FLT3/ACVR1 to overcome FLT3 inhibitor resistance and hinder AML growth synergistically with venetoclax.TP-0184抑制FLT3/ACVR1以克服FLT3抑制剂耐药性,并与维奈托克协同阻碍急性髓系白血病的生长。
Leukemia. 2024 Jan;38(1):82-95. doi: 10.1038/s41375-023-02086-6. Epub 2023 Nov 25.
9
Perspectives and challenges of small molecule inhibitor therapy for FLT3-mutated acute myeloid leukemia.FLT3 突变型急性髓系白血病小分子抑制剂治疗的观点与挑战。
Ann Hematol. 2024 Jul;103(7):2215-2229. doi: 10.1007/s00277-023-05545-3. Epub 2023 Nov 17.
10
A Year of Advances in Precision Therapy for Blood Cancers.血液癌症精准治疗的一年进展。
Blood Cancer Discov. 2023 Nov 1;4(6):423-426. doi: 10.1158/2643-3230.BCD-23-0193.